Selective Targeting of Disease-Relevant Protein Binding Domains by O-Phosphorylated Natural Product Derivatives-Reference-Cited by-同舟云学术

Selective Targeting of Disease-Relevant Protein Binding Domains by O-Phosphorylated Natural Product Derivatives

Published:2011-08-10 Issue:10 Volume:6 Page:1008-1014
ISSN:1554-8929
Container-title:ACS Chemical Biology
language:en
Short-container-title:ACS Chem. Biol.

Author:

Gräber Martin¹²,Janczyk Weronika³,Sperl Bianca¹,Elumalai Nagarajan²,Kozany Christian⁴,Hausch Felix⁴,Holak Tad A.³,Berg Thorsten¹²

Affiliation:

1. Department of Molecular Biology, Max Planck Institute of Biochemistry, and Center for Integrated Protein Science Munich (CIPSM), Am Klopferspitz 18, 82152 Martinsried, Germany

2. Institute of Organic Chemistry, University of Leipzig, Johannisallee 29, 04103 Leipzig, Germany

3. Research Group NMR Spectroscopy, Max Planck Institute of Biochemistry, Am Klopferspitz 18, 82152 Martinsried, Germany

4. Chemical Genomics Research Group, Max Planck Institute of Psychiatry, Kraepelinstrasse 2, 80804 Munich, Germany

Publisher

American Chemical Society (ACS)

Subject

Molecular Medicine,General Medicine,Biochemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/cb2001796

Reference38 articles.

1. Reaching for high-hanging fruit in drug discovery at protein–protein interfaces

2. Molecular Understanding and Modern Application of Traditional Medicines: Triumphs and Trials

3. Natural product inhibitors of protein–protein interactions mediated by Src-family SH2 domains

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent advances of Pin1 inhibitors as potential anticancer agents;Bioorganic Chemistry;2024-03

2. A straightforward access to trifluoromethylated natural products through late-stage functionalization;Natural Product Reports;2023

3. Stafiba: A STAT5‐Selective Small‐Molecule Inhibitor;ChemBioChem;2022-11-24

4. A High-Throughput Fluorescence Polarization-Based Assay for the SH2 Domain of STAT4;Methods and Protocols;2022-11-23

5. The fellowship of the RING: BRCA1, its partner BARD1 and their liaison in DNA repair and cancer;Pharmacology & Therapeutics;2021-10